Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for CTD-associated Thrombocytopenia
NCT05998759Phase 2Recruiting
- Sponsor
- Beijing Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in Thrombocytopenia, sponsored by Beijing Hospital. Started Dec 2023; status: recruiting.
02
Drugs
telitacicept
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT05998759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998759.